As­traZeneca CEO Pas­cal So­ri­ot aims for 15 new drug launch­es by 2030

As­traZeneca CEO Pas­cal So­ri­ot on Thurs­day un­veiled am­bi­tious plans to launch 15 new drugs by 2030 — and he’s wast­ing no time, with 30 Phase III tri­al ini­ti­a­tions planned this year.

So­ri­ot spies block­buster po­ten­tial in 10 of those pro­grams, he said on the com­pa­ny’s quar­ter­ly earn­ings call, in­clud­ing the com­pa­ny’s oral SERD camizes­trant in ER+/HER2- breast can­cer and Cin­Cor’s bax­dro­stat in hy­per­ten­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER